Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia, Myeloid, Acute 9Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Hematologic Neoplasms 3Philadelphia Chromosome 2Mastocytosis, Systemic 2Leukemia, Mast-Cell 2Leukemia 2Hematologic Diseases 2Bronchiolitis Obliterans Syndrome 2Bone Marrow Diseases 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Translocation, Genetic 1Pathologic Processes 1Neurofibroma, Plexiform 1Neuroblastoma 1Neoplastic Processes 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Histiocytosis, Langerhans-Cell 1

Interventions

bosutinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Pathologic Processes × Myeloid × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡